FENC
BUYMeanRevComposite
65.60
Technical
95.50
Fundamental
55.60
Rank
—
Price
12.78
Hurst
0.29
As of
Aug 12, 2026
Daily
Fennec Pharmaceuticals Inc.
HealthcareBiotechnologyFennec Pharmaceuticals is a biopharmaceutical company that commercializes PEDMARK, a sodium thiosulfate-based treatment designed to protect children from hearing damage caused by cisplatin chemotherapy. The company distributes its product through pediatric cancer specialists and maintains research partnerships to evaluate the drug's effectiveness in older patient populations. Based in North Carolina, Fennec was formerly known as Adherex Technologies before rebranding in 2014.
Market cap
$359.1M
P/E (trailing)
—
P/E (forward)
10.80
PEG ratio
1.47
Dividend yield
0.00%
Beta
1.23
52w range
5.65 – 13.25
Return on equity
-18.58%
Profit margin
-5.49%
Revenue growth
+85.20%
Earnings growth
—
Price history
1Y: 10.24 (+24.9%) · range 5.77–12.78
Cycle position
47/ 100 cycle scoreMID-BULL
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 25 · NOT READY · exit proximity 0
Conviction
33/ 100 · maturity 0%
Buildup.3326
EMA entry setup.4225
Fundamentals.2556
Volume profile
POC
10.20
Price vs POC
+0.4%
Overhead supply
55%
Runway
+0.8%
Value area 8.83–11.43 · 55% of 120d volume overhead · heavy supply
Contributing sources
No source detections in the last 21 days.
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -4.48% | +6.09% | mature |
| 40d | -10.14% | +6.09% | mature |